Apnimed
The combination drug composed of aroxybutynin and atomoxetine, designated AD109, is being developed by Apnimed for the treatment of obstructive sleep apnea (OSA). The present study is a Phase 3 open label continuation protocol enrolling qualifying participants who completed one of the parent Phase 3 double-blind placebo-controlled studies, APC-APN-304 or APC-APN-305.
Inclusion Criteria: * Completion of APC-APN-304 without permanent discontinuation of IMP. * Completion of APC-APN-305 without permanent discontinuation of IMP. Exclusion Criteria: * Participants are excluded from the study if participation would be considered unsafe by the investigator based on the individual's current status. * Participants are excluded from the study if participation would be considered unsafe by the investigator based on concomitant therapies.
Fixed Dose Combination